Most earnings reports tell you about a company. This one tells you about the country.

Intuitive Surgical, which makes the da Vinci surgical robot, reported second-quarter revenue of $2.89 billion, up 19% year over year, with non-GAAP EPS of $2.80 against a $2.48 consensus. A clear beat. The shares fell sharply anyway, because investors looked past the headline to the number that actually drives the business: US da Vinci procedure growth slowed to 12% from 14% in the first quarter.

The reason that number is worth attention beyond the stock is what it measures.

Why this company is an unusually clean policy indicator

Roughly 85% of Intuitive's quarterly revenue is recurring, tied to instruments, accessories, leasing, and service that scale with how many operations actually happen. The company does not primarily sell robots; it sells the consumables consumed when surgeons use them.

That makes its procedure count a near-real-time census of surgical volume across nearly 13,000 installed systems. And a meaningful share of those procedures are what management calls benign procedures, a subset of which can be deferred, hernia repairs, gallbladder removals, gynecologic surgery. Necessary eventually, postponable now.

Deferrable surgery is exactly the category that responds to whether people can afford care. Which means this company's quarterly numbers function as a live readout on American health coverage, reported faster than most government data and audited more rigorously than most surveys.

What management actually said about the ACA

The language on the earnings call was careful, and worth quoting precisely. Based on customer feedback, the company said it believes there was a modest adverse impact to Q2 US da Vinci procedure growth from those patients impacted by the expiration of subsidies for ACA enhanced premiums, and that looking at benign procedures, a slight moderation in procedure growth rate started in Q1.

Note the hedging: modest, slight, based on customer feedback. Analysts pushed on whether slower growth reflected ACA changes or simply a larger installed base producing slower percentage growth, and the company said it sees both factors at work. That is an honest answer and a real caveat: a company growing off a bigger base naturally posts lower percentage growth, and disentangling that from a coverage effect is genuinely difficult.

But the direction is consistent with everything else known about 2026. Enhanced ACA subsidies expired at the end of 2025, out-of-pocket premiums roughly doubled for subsidized enrollees, and marketplace enrollment fell by roughly three million. Policy analysis predicted people would defer care. Here is a company with visibility into millions of operations reporting, cautiously, that deferral appears to be happening.

That is what makes this significant beyond one stock. Most evidence about coverage loss is either projection or survey. This is a transaction count.

The distinction investors seem to have collapsed

The second headwind is GLP-1 drugs, and it is a fundamentally different kind of problem. US bariatric cases declined in the high single digits during the quarter as obesity medications altered treatment patterns.

Here is the distinction that matters more than the quarter: one of these headwinds is deferral and the other is substitution.

Deferral means the procedure is postponed, not eliminated. A hernia does not resolve because someone lost their subsidy; it gets repaired later, often after becoming more urgent and more expensive. Management expects deferred procedures to return over time, and for the company that is probably right. The demand is stored, not destroyed.

Substitution is different. A patient who achieves durable weight loss on a GLP-1 does not have a bariatric surgery pending. That operation is not delayed, it is gone, replaced by a pharmaceutical. Those cases do not come back when coverage improves or the economy strengthens.

Investors appear to have priced both as generic bad news. They are not equivalent. One is a timing problem that resolves; the other is permanent structural erosion of a procedure category. For anyone modeling this business, or thinking about surgical volumes generally, that distinction does most of the analytical work.

There is a second-order effect too. The mix shift toward more cholecystectomy and fewer bariatric cases reduced instrument and accessory revenue per procedure. GLP-1s do not just remove volume, they remove some of the most instrument-intensive volume, degrading the revenue mix of the procedures that remain.

The self-inflicted wound that is probably strategic

The other thing that unsettled investors was voluntary. Intuitive announced an Extended Use Program that will lengthen instrument life beginning in 2027, which could lower instrument revenue per procedure over time, even if it helps expand access. Pricing has not been finalized, and force feedback instruments and stapling and energy products will not be part of the program.

A company whose economics rest on consumables is choosing to make those consumables last longer. Read defensively, that is margin erosion. Read strategically, it is a company with dominant share deciding that cost-constrained hospitals and ambulatory surgery centers are the next growth frontier, and lowering per-procedure cost to reach them, alongside the XiR system aimed at the same segment. Trading revenue per procedure for procedures is a reasonable bet when your installed base is the moat.

Two things worth noting for accuracy

Reported non-GAAP gross margin of 70% included a $36 million pretax tariff refund; excluding it, the figure would have been 68.7%. Still an improvement year over year, but part of the headline margin strength was one-time rather than recurring.

And the US softness is not global. International da Vinci procedure growth ran 20%, with Europe and Asia each up 20% and the rest of the world up 22%, with particular strength in India, Italy, Taiwan, and the UK. China is the exception, with only two systems placed amid lower tender activity, domestic competition, and policy-driven pricing pressure.

That contrast is itself informative. The same technology, the same clinical value, growing at 20% in markets with universal coverage and 12% in the United States. The constraint slowing US growth is not surgical demand or technological adoption. It is who can afford to have the operation.

What to take from it

The company maintained full-year da Vinci procedure growth guidance of 13.5% to 15.5%, expecting to land near the midpoint, and explicitly built ACA subsidy changes, China, European capital pressure, and obesity pharmaceuticals into that range. Management is not panicking, and the underlying business grew revenue 19%.

The broader point is the one worth carrying. When Congress let enhanced subsidies expire, the predicted consequence was that people would skip or delay care. That prediction is now showing up in the operating results of a company that counts operations for a living. Policy debates tend to run on projections and competing models. This is a count of surgeries that did not happen this quarter, and the people they did not happen to still have the conditions that made the surgery necessary.

Further reading